Minor
Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment · Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Trial sites expanded: 118 → 139 locations
ArriVent BioPharma, Inc.Phase 3 NCT07185997 Registry history of NCT07185997 on ClinicalTrials.gov (opens the registry)